drugset / Trial / NCT06602063
Surgery for Relapsed Ovarian Cancer in Precision
Phase 1/2
Not yet recruiting
33 enrolled
Shanghai Gynecologic Oncology Group
Shanghai Zhongshan Hospital · collabTongji Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC).
Timeline
- Start
- 2025-07
- Primary completion
- 2030-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | Intravenous |